LIAN News and Press, LianBio From 10/24/23

2023-10-24 17:37:02 ET Gainers: Vitru  ( VTRU ) +15% . Scholar Rock Holding  ( SRRK ) +7% . LianBio ( LIAN ) +5% . 908 Devices  ( MASS ) +5% . Microsoft Corporation ( MSFT ) +4% . Losers: Forbion European A...

2023-10-24 14:49:41 ET Gainers: LianBio ( LIAN ) +122% . Falcon's Beyond Global ( FBYD ) +39% . Tourmaline Bio ( TRML ) +29% . Aspen Aerogels ( ASPN ) +26% . Worksport Ltd ( WKSP ) +25% . Agilysys AGYS +25% . Immunity...

2023-10-24 12:40:16 ET Shares of LianBio (NASDAQ: LIAN) were skyrocketing 132.4% higher as of 11:11 a.m. ET on Tuesday. The huge gain came after the company announced that it entered into an agreement to hand over exclusive rights to market cardiomyopathy drug mavacamten in mainland...

2023-10-24 09:02:45 ET Whether you’re trading penny stocks or stocks over $100, the goal is the same. You want to find opportunities as early as possible and capitalize. In the stock market today, there are plenty of factors affecting the way investors approach both long-term and...

2023-10-24 08:38:45 ET More on LianBio Seeking Alpha’s Quant Rating on LianBio Historical earnings data for LianBio Financial information for LianBio For further details see: LianBio shares soars after agreement with Bristol Myers Squibb

2023-10-24 07:33:36 ET DENVER, Colo., Oct 24, 2023 ( www.247marketnews.com )- LianBio (NASDAQ: LIAN) stated, this morning, that Bristol Myers Squibb(NYSE: BMY) obtained LianBio’s exclusive rights, for a total upfront consideration of $350 million, to develop and commercialize mav...

LianBio to receive total upfront consideration of $350 million LianBio Board of Directors to conduct strategic review of business SHANGHAI and PRINCETON, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to...

EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak gradient, LVOT obstruction, clinical symptoms, health status, cardiac biomarkers, and ...

Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration ( NMPA) Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint Data fro...

SHANGHAI, China and PRINCETON, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in its Phase 1 clinical trial...